Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S103 CAR-T in Refractory Generalized Myasthenia Gravis
NCT06958939Phase 1Active, not recruiting
- Start
- May 2025
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of senl-103 in generalized myasthenia gravis (gMG). Primary endpoint: Dose-limiting toxicity at 28 days. Started May 2025; status: active, not recruiting.
02
Drugs
senl-103
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on NCT06958939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958939.